» Articles » PMID: 29743369

Intrastructural Help: Harnessing T Helper Cells Induced by Licensed Vaccines for Improvement of HIV Env Antibody Responses to Virus-Like Particle Vaccines

Overview
Journal J Virol
Date 2018 May 11
PMID 29743369
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Induction of persistent antibody responses by vaccination is generally thought to depend on efficient help by T follicular helper cells. Since the T helper cell response to HIV Env may not be optimal, we explored the possibility of improving the HIV Env antibody response to virus-like particle (VLP) vaccines by recruiting T helper cells induced by commonly used licensed vaccines to provide help for Env-specific B cells. B cells specific for the surface protein of a VLP can internalize the entire VLP and thus present peptides derived from the surface and core proteins on their major histocompatibility complex class II (MHC-II) molecules. This allows T helper cells specific for the core protein to provide intrastructural help for B cells recognizing the surface protein. Consistently, priming mice with an adjuvanted Gag protein vaccine enhanced the HIV Env antibody response to subsequent booster immunizations with HIV VLPs. To harness T helper cells induced by the licensed Tetanolpur vaccines, HIV VLPs that contained T helper cell epitopes of tetanus toxoid were generated. Tetanol-immunized mice raised stronger antibody responses to immunizations with VLPs containing tetanus toxoid T helper cell epitopes but not to VLPs lacking these epitopes. Depending on the priming immunization, the IgG subtype response to HIV Env after the VLP immunization could also be modified. Thus, harnessing T helper cells induced by other vaccines appears to be a promising approach to improve the HIV Env antibody response to VLP vaccines. Induction of HIV Env antibodies at sufficient levels with optimal Fc effector functions for durable protection remains a challenge. Efficient T cell help may be essential to induce such a desirable antibody response. Here, we provide proof of concept that T helper cells induced by a licensed vaccine can be harnessed to provide help for HIV Env-specific B cells and to modulate the Env-specific IgG subtype response.

Citing Articles

A viral vaccine design harnessing prior BCG immunization confers protection against Ebola virus.

Ng T, Furuyama W, Wirchnianski A, Saavedra-Avila N, Johndrow C, Chandran K Front Immunol. 2024; 15:1429909.

PMID: 39081315 PMC: 11286471. DOI: 10.3389/fimmu.2024.1429909.


Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention.

Tarres-Freixas F, Clotet B, Carrillo J, Blanco J Vaccines (Basel). 2024; 12(3).

PMID: 38543932 PMC: 10975260. DOI: 10.3390/vaccines12030298.


Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine component.

Su J, Harati Taji Z, Kosinska A, Ates Oz E, Xie Z, Bielytskyi P JHEP Rep. 2024; 6(4):100997.

PMID: 38425450 PMC: 10904195. DOI: 10.1016/j.jhepr.2023.100997.


Immunogenicity of Recombinant Lipid-Based Nanoparticle Vaccines: Danger Signal vs. Helping Hand.

Temchura V, Wagner J, Damm D Pharmaceutics. 2024; 16(1).

PMID: 38258035 PMC: 10818441. DOI: 10.3390/pharmaceutics16010024.


Modulation of immune responses to liposomal vaccines by intrastructural help.

Damm D, Suleiman E, Wagner J, Klessing S, Pfister F, Elsayed H Eur J Pharm Biopharm. 2023; 192:112-125.

PMID: 37797679 PMC: 10872448. DOI: 10.1016/j.ejpb.2023.10.003.


References
1.
McKinstry W, Hijnen M, Tanwar H, Sparrow L, Nagarajan S, Pham S . Expression and purification of soluble recombinant full length HIV-1 Pr55(Gag) protein in Escherichia coli. Protein Expr Purif. 2014; 100:10-8. DOI: 10.1016/j.pep.2014.04.013. View

2.
Rice J, Elliott T, Buchan S, Stevenson F . DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines. J Immunol. 2001; 167(3):1558-65. DOI: 10.4049/jimmunol.167.3.1558. View

3.
Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A . Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol. 1989; 19(12):2237-42. DOI: 10.1002/eji.1830191209. View

4.
Trumpfheller C, Caskey M, Nchinda G, Paula Longhi M, Mizenina O, Huang Y . The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci U S A. 2008; 105(7):2574-9. PMC: 2268178. DOI: 10.1073/pnas.0711976105. View

5.
Pollara J, Easterhoff D, Fouda G . Lessons learned from human HIV vaccine trials. Curr Opin HIV AIDS. 2017; 12(3):216-221. PMC: 5389590. DOI: 10.1097/COH.0000000000000362. View